中国医药
中國醫藥
중국의약
CHINA MEDICINE
2010年
7期
609-610
,共2页
急性脑梗死%GM1神经节苷脂%早期康复%治疗效果
急性腦梗死%GM1神經節苷脂%早期康複%治療效果
급성뇌경사%GM1신경절감지%조기강복%치료효과
Acute cerebral infarction%Gangliosides GM1%Early rehabilitation%Effectiveness,treatment
目的 观察神经节苷脂GM1联合早期康复治疗急性脑梗死(ACI)的临床疗效及安全性评价.方法 符合入选标准的6～72 h内急性脑梗死患者30例,接受神经节苷脂GM1联合早期康复治疗(治疗组),并与同期未接受神经节苷脂GM1治疗的30例急性脑梗死患者(对照组)对比研究.2组均常规使用改善脑循环+抗血小板聚集药等,若梗死面积较大,加用脱水剂.所有患者均配合早期康复训练,即患者入院后第1天开始康复训练.根据病情选用适当训练方式,包括肢体摆放、关节活动及日常生活活动能力训练等,1次/d,每次1 h.神经节苷脂GM1治疗组在常规治疗基础上加用生理盐水250 ml+神经节苷脂GM1100 mg,静脉滴注1 h以上,连续14 d为1个疗程.结果 治疗7、21、90 d后治疗组美国国立卫生院卒中量表评分分别为(10.9±8.6)、(8.5±4.7)、(6.1±3.3)分,对照组分别为(14.7±8.6)、(11.3±7.6)、(9.0±4.2)分,2组比较差异有统计学意义(均P＜0.01).治疗后21、90 d治疗组的Barthel指数评分分别为(89.7±8.3)、(95.8±4.5)分,对照组分别为(72.8±10.5)、(80.8±5.7)分,2组比较差异有统计学意义(均P＜0.01).2组均未见明显药物不良反应.结论 神经节苷脂GM1联合早期康复是一种改善急性脑梗死患者神经功能缺失和提高患者日常生活能力的有效方案.
目的 觀察神經節苷脂GM1聯閤早期康複治療急性腦梗死(ACI)的臨床療效及安全性評價.方法 符閤入選標準的6～72 h內急性腦梗死患者30例,接受神經節苷脂GM1聯閤早期康複治療(治療組),併與同期未接受神經節苷脂GM1治療的30例急性腦梗死患者(對照組)對比研究.2組均常規使用改善腦循環+抗血小闆聚集藥等,若梗死麵積較大,加用脫水劑.所有患者均配閤早期康複訓練,即患者入院後第1天開始康複訓練.根據病情選用適噹訓練方式,包括肢體襬放、關節活動及日常生活活動能力訓練等,1次/d,每次1 h.神經節苷脂GM1治療組在常規治療基礎上加用生理鹽水250 ml+神經節苷脂GM1100 mg,靜脈滴註1 h以上,連續14 d為1箇療程.結果 治療7、21、90 d後治療組美國國立衛生院卒中量錶評分分彆為(10.9±8.6)、(8.5±4.7)、(6.1±3.3)分,對照組分彆為(14.7±8.6)、(11.3±7.6)、(9.0±4.2)分,2組比較差異有統計學意義(均P＜0.01).治療後21、90 d治療組的Barthel指數評分分彆為(89.7±8.3)、(95.8±4.5)分,對照組分彆為(72.8±10.5)、(80.8±5.7)分,2組比較差異有統計學意義(均P＜0.01).2組均未見明顯藥物不良反應.結論 神經節苷脂GM1聯閤早期康複是一種改善急性腦梗死患者神經功能缺失和提高患者日常生活能力的有效方案.
목적 관찰신경절감지GM1연합조기강복치료급성뇌경사(ACI)적림상료효급안전성평개.방법 부합입선표준적6～72 h내급성뇌경사환자30례,접수신경절감지GM1연합조기강복치료(치료조),병여동기미접수신경절감지GM1치료적30례급성뇌경사환자(대조조)대비연구.2조균상규사용개선뇌순배+항혈소판취집약등,약경사면적교대,가용탈수제.소유환자균배합조기강복훈련,즉환자입원후제1천개시강복훈련.근거병정선용괄당훈련방식,포괄지체파방、관절활동급일상생활활동능력훈련등,1차/d,매차1 h.신경절감지GM1치료조재상규치료기출상가용생리염수250 ml+신경절감지GM1100 mg,정맥적주1 h이상,련속14 d위1개료정.결과 치료7、21、90 d후치료조미국국립위생원졸중량표평분분별위(10.9±8.6)、(8.5±4.7)、(6.1±3.3)분,대조조분별위(14.7±8.6)、(11.3±7.6)、(9.0±4.2)분,2조비교차이유통계학의의(균P＜0.01).치료후21、90 d치료조적Barthel지수평분분별위(89.7±8.3)、(95.8±4.5)분,대조조분별위(72.8±10.5)、(80.8±5.7)분,2조비교차이유통계학의의(균P＜0.01).2조균미견명현약물불량반응.결론 신경절감지GM1연합조기강복시일충개선급성뇌경사환자신경공능결실화제고환자일상생활능력적유효방안.
Objective To evaluate the clinical efficacy and safety of monosialoganglioside(GM1 ) combined with early rehabilitation treatment of acute cerebral infarctions. Methods According to the inclusive and exclusive standards, 30 patients suffering acute cerebral infarctions between 6 hr and 72 hr were selected as a test group of GM1 combined with early rehabilitation treatment on acute cerebral infarctions. At the same time, other 30 patients were also selected as a control group. Clinical efficacy was evaluated according to changes of NIHSS and Barthel scores between two groups on the 21st day and 90th day. Results There was a significant difference of NIHSS scores between the test group and the control group( P ＞ 0.05 )on the 21st day and 90th day. There was also a significant difference of Barthel scores between the test group and the control group(P ＞0.01 ). No significant adverse reaction was observed. Conclusion GM1 combined with early rehabilitation therapy is an effective method of improving the neurological function impairment of acute cerebral infarction patients.
